Gentamicin

CAT:
804-HY-A0276A-01
Size:
5 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Gentamicin - image 1

Gentamicin

  • Description:

    Gentamicin, an orally active aminoglycoside antibiotic, inhibits the growth of both gram-positive and gram-negative bacteria and to inhibit several strains of mycoplasma in tissue culture. Gentamicin inhibits DNase I with an IC50 of 0.57 mM[1][2][3][4].
  • UNSPSC:

    12352005
  • Hazard Statement:

    H317, H334
  • Target:

    Antibiotic; Bacterial
  • Type:

    Reference compound
  • Related Pathways:

    Anti-infection
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Infection; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/gentamicin.html
  • Solubility:

    H2O : 175 mg/mL (ultrasonic)
  • Smiles:

    O[C@]1(C)C(NC)[C@@H](O)[C@@H](O[C@H]2C(N)C[C@H](N)[C@@H](O[C@@H]3[C@H](N)CC[C@@H]([R])O3)[C@@H]2O)OC1.NC[*].C[C@H]([*])N.C[C@H]([*])NC.[R=].[or].[or]
  • Molecular Formula:

    C (19-21) H (39-43) N5O7
  • Precautions:

    H317, H334
  • References & Citations:

    [1]Xu W, et al. A rapid and sensitive method for kinetic study and activity assay of DNase I in vitro based on a GO-quenched hairpin probe. Anal Bioanal Chem. 2016 May;408 (14) :3801-9.|[2]Rudin A, et al. Antibacterial activity of gentamicin sulfate in tissue culture. Appl Microbiol. 1970 Dec;20 (6) :989-90.|[3]Kumar CG, et al. Microbial biosynthesis and applications of gentamicin: a critical appraisal. Crit Rev Biotechnol. 2008;28 (3) :173-212.|[4]Espersen F, et al. Effect of treatment with methicillin and gentamicin in a new experimental mouse model of foreignbody infection. Antimicrob Agents Chemother. 1994 Sep;38 (9) :2047-53.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, protect from light, stored under nitrogen)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Launched
  • Isoform:

    Aminoglycoside
  • Citation 01:

    AMB Express. 2024 Dec 24;14 (1) :141.|Bio Protoc. 2025 Feb 20;15 (4) :e5221.|Biochem Pharmacol. 2025 Sep 17;242:117343.|Biomed Pharmacother. 2023 Dec 31:169:115856.|bioRxiv. 2024 May 10.|BMC Microbiol. 2025 Apr 29;25 (1) :257.|Cancer Res. 2025 Oct 9.|Cell. 2024 Feb 15;187 (4) :882-896.e17|Chin J Traumatol. 2024 Jul 3:S1008-1275 (24) 00075-0.|Curr Microbiol. 2023 May 31;80 (7) :230.|Curr Microbiol. 2025 Aug 16;82 (10) :456.|Curr Res Food Sci. 2025 May 16:10:101084.|Cytotherapy. 2025 Sep 13.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Exp Eye Res. 2025 Oct 16:262:110698.|Food Chem. 2023 Mar 1:403:134399.|Food Funct. 2025 Feb 3;16 (3) :1041-1059.|Future Microbiol. 2025 Oct 13:1-10.|Infect Genet Evol. 2025 Sep:133:105780.|Int Immunopharmacol. 2025 May 21:159:114888.|Int J Biol Macromol. 2025 May;305 (Pt 2) :141278.|Int J Infect Dis. 2026 Jan:162:108165.|Int J Med Microbiol. 2023 Mar 28;313 (2) :151578.|MedComm (2020) . 2025 Jan 8;6 (1) :e70046.|Microbiol Spectr. 2025 Aug 29:e0059025.|Microbiol Spectr. 2025 May 19:e0307424.|Microbiol Spectr. 2025 Oct 16:e0160325.|Microorganisms. 2024 Mar 13;12 (3) :575.|Microorganisms. 2025 Apr 18;13 (4) :938.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398 (4) :3681-3695.|Patent. US20240319170A1|Pathogens. 2024 Nov 15;13 (11) :1003.|Physiol Res. 2025 Mar 24;74 (1) :79-92. |Transl Lung Cancer Res. 2025 Jun 30;14 (6) :2159-2179.|Vet Microbiol. 2024 May:292:110046.|Vet Res Commun. 2024 Dec;48 (6) :3859-3872.|Virulence. 2024 Dec;15 (1) :2415952.|World J Gastroenterol. 2025 Jul 28;31 (28) :107361.|ACS Appl Mater Interfaces. 2019 Oct 16;11 (41) :38190-38204. |ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|Am J Physiol Cell Physiol. 2019 Aug 1;317 (2) :C277-C286.|Appl Microbiol Biotechnol. 2022 Apr;106 (7) :2689-2702.|Aquaculture. 2021, 736248.|Autophagy. 2025 Jul 27:1-23.|Cancer Cell. 2025 Jul 29:S1535-6108 (25) 00318-6.|Cell Death Dis. 2023 Jan 11;14 (1) :15.|Cell Host Microbe. 2024 Jul 23:S1931-3128 (24) 00254-3.|Cell Transplant. 2021 Jan-Dec:30:963689721997151.|Evid Based Complement Alternat Med. 2015:2015:639412.|Immun Inflamm Dis. 2024 Jul;12 (7) :e1149.|Int J Biol Sci. 2024 Oct 7;20 (14) :5415-5435.|J Ethnopharmacol. 2020 Sep 15;259:112882. |Mol Immunol. 2017 Dec:92:151-160.|Mol Med Rep. 2016 Dec;14 (6) :5304-5310.|Mutat Res Genet Toxicol Environ Mutagen. 2023 May-Jun:888:503636.|Nat Aging. 2025 May;5 (5) :848-867.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Research Square Print. October 6th, 2022.|Toxicology. 2023 Jan 1:483:153386.
  • CAS Number:

    [1403-66-3]